<code id='885AC5297F'></code><style id='885AC5297F'></style>
    • <acronym id='885AC5297F'></acronym>
      <center id='885AC5297F'><center id='885AC5297F'><tfoot id='885AC5297F'></tfoot></center><abbr id='885AC5297F'><dir id='885AC5297F'><tfoot id='885AC5297F'></tfoot><noframes id='885AC5297F'>

    • <optgroup id='885AC5297F'><strike id='885AC5297F'><sup id='885AC5297F'></sup></strike><code id='885AC5297F'></code></optgroup>
        1. <b id='885AC5297F'><label id='885AC5297F'><select id='885AC5297F'><dt id='885AC5297F'><span id='885AC5297F'></span></dt></select></label></b><u id='885AC5297F'></u>
          <i id='885AC5297F'><strike id='885AC5297F'><tt id='885AC5297F'><pre id='885AC5297F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          entertainment

          author:explore    - browse:9677
          Scorecard
          Ryan Pierse/Getty Images

          Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

          In December, Vertex Pharmaceuticalsannounced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.

          advertisement

          The next big test of Alnylam Pharmaceuticals’pipeline of RNA-interference medicines looms with the outcome of a Phase 3 study called HELIOS-B that is investigating vutrisiran as a treatment for ATTR-CM, a progressive disease that leads to heart failure.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore